Clinical Effect and Safety of CCLG-ALL 2008 (high risk group) Protocol in the Treatment of Childhood Mixed Phenotype Acute Leukemia.
10.19746/j.cnki.issn.1009-2137.2021.01.008
- Author:
Yong-Zhi ZHENG
1
;
Shao-Hua LE
1
;
Hao ZHENG
1
;
Xue-Ling HUA
1
;
Zai-Sheng CHEN
1
;
Ling ZHENG
1
;
Cai CHEN
1
;
Mei LI
1
;
Chun-Xia CAI
1
;
Jing-Hui YANG
1
;
Yi-Qiao CHEN
1
;
Qin-Li GAO
1
;
Ying-Ying CHEN
1
;
Li-Li PAN
1
;
Jian LI
2
;
Jian-Da HU
3
Author Information
1. Department of Pediatric Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China.
2. Department of Pediatric Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China,E-mail:1354113723@qq.com.
3. Department of Pediatric Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China,E-mail：drjiandahu@163.com.
- Publication Type:Journal Article
- MeSH:
Child;
Disease-Free Survival;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myeloid, Acute;
Phenotype;
Prognosis;
Remission Induction;
Retrospective Studies
- From:
Journal of Experimental Hematology
2021;29(1):49-55
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical effect and safety of Chinese Children's Leukemia Group (CCLG)-ALL 2008 (high risk group) protocol in the treatment with childhood Mixed phenotype acute leukemia (MPAL).
METHODS:The clinical data of 15 new diagnosed patients with MPAL treated in our hospital from January 2013 to December 2017 were retrospectively analyzed, and received CCLG-ALL 2008 (high risk group) protocol chemotherapy.
RESULTS:One patient gave up treatment after diagnosed, and 14 children with MPAL after induction remission chemotherapy, 3 patients gave up, and 5 patients received consolidation chemotherapy, and 6 patients received allogeneic hematopoietic stem cell transplantation (allo-HSCT). The complete remission (CR) rate was 85.7% at d33 of induction remission chemotherapy. The serious adverse event and treatment-related mortality (TRM) rate was 71.4% and 14.3%, respectively. The recurrence rate was 21.4% and the median time of relapse was 12(9.7-18.4) months. Except for 4 patients who gave up treatment, the 5-year event-free survival (EFS) rate in the other 11 patients was (54.5±15.0)%. The 5 years EFS of 4 patients who received consolidation chemotherapy was significantly lower than the 6 patients who received allo-HSCT after CR (25.0%±21.7% vs 83.3%±15.2%, P=0.033).
CONCLUSION:The CCLG-ALL2008 (for high-risk group) protocol in treatment of children with MPAL can get a high CR rate, but also with a high incidence of SAE. The patients received allo-HSCT after CR may have a good prognosis.
